Can Ofatumumab be reimbursed for the second time?

Ofatumumab in combination with chlorambucil for the treatment of patients with previously untreated chronic lymphocytic leukemia (CLL) who are considered unfit to receive fludarabine-based therapy TreatmentIn patients with relapsed or progressiveCLL,ofatumumab is indicated for extended treatment in patients with relapsed or progressive chronic lymphocytic leukemia who have achieved a complete or partial response after at least two prior therapies.

Ofatumumab is also indicated for the treatment of patients with chronic lymphocytic leukemia who are refractory to fludarabine and alemtuzumab. The mean steady-state half-life in patients with chronic lymphocytic leukemia is 17.1 days. Similarly, the steady-state elimination half-life in patients with subcutaneous ofatumumab is estimated to be 16 days. Ofatumumab is also indicated for the treatment of adult patients with relapsing forms of multiple sclerosis, including active secondary progressive disease, clinically isolated syndrome, and relapsing-remitting disease.

The original drug of ofatumumab has been launched in China and has also been included in the medical insurance. It is only reimbursed for patients who meet the indications. The price is around tens of thousands of yuan. The reimbursement ratio is different in different regions. The price after reimbursement may be different. The conditions for the second reimbursement may need to be based on the policies of the local medical insurance bureau. The European version of ofatumumab original drug specifications20mg/0.4mL each sold overseas may cost around RMB 16,000 (the price may fluctuate due to the exchange rate). It is expensive and there are currently no generics of ofatumumab. For more drug information and specific prices, please consult a medical consultant.